purpurea, the gentamicin-producing organism, were obtained which require an exogenous source of 2-deoxystreptamine in order to produce gentamicin. Streptamine incorporation afforded a mixture of 2-hydroxygentamicin C as a complex of essentially the C1 and C2 components whereas 2-deoxystreptamine when incorporated by the same idiotroph afforded the same mixture of C,, C2 and C2 gentamicins as the parent (m1) organism.
The 2-hydroxygentamicin C complex exhibited broad-spectrum antibiotic activity with an in vitro potency less than that for the gentamicin C complex , but with greater activity against selected gentamicin C resistant organisms . The LD50 (i.v.) in mice of the 2-hydroxygentamicin C complex indicated that it had approximately half the toxicity of the gentamicin C complex . 2, 5-Dideoxystreptamine afforded a C1, C2, and C1a mixture of 5-deoxygentamicins, which also had broad spectrum activity , and exhibited improved activity against several gentamicin-acetylating strains of resistant bacteria.
The LD50 (i.v.) in mice of the 5-deoxygentamicin C complex indicated that it was about 2.5 times more toxic than the gentamicin C complex . Two derivatives of 2, 5-dideoxystreptamine afforded the same mixture of 5-deoxygentamicins.
2-Epistreptamine upon supplementation to a broth containing growing cultures of these idiotrophs also produced antibiotic . growth from these slants was transferred to flasks containing medium 2 consisting of (per liter, distilled H2O) beef extract, 3 g; tryptone, 5 g; dextrose, 1 g; soluble starch, 24 g; yeast extract, 5g; and calcium carbonate, 4 g and incubated for 4 days at 37°C on a rotary shaker. From this first stage seed a 10 % inoculum was transferred to medium 2 and fermentation was conducted as above at 28°C for 7-8 days.
Mutation Methods and Selection of Deoxystreptamine-Requiring Mutants
The organism was grown in medium 2 for 3 days at 37°C and the resultant cells were harvested by centrifugation, washed and resuspended in a phosphate-buffered saline solution (pH 7.1) resulting in a final cell volume of 7 %. This suspension was treated with the mutagenic agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) at 500ug/ml for 30 minutes. The mutagenized culture was then centrifuged, decanted and washed with buffered saline. The resulting cell mass was resuspended in buffered saline solution and was vigorously shaken with 12 mesh silicon carbide granules (Hengar Co., Phil., Pa). Ten-fold serial dilutions were made in buffered saline solution and aliquots were plated in a medium (medium 3) containing (per liter, distilled H2O) trypticase glucose extract, 5 g; trypticase peptone, 3 g; glucose, 1 g; agar, 15 g and incubated at 37°C until colonies were evident (about 7 days). Well isolated colonies were picked to duplicate plates (medium 3), one set of which was overlaid with a spore suspension of Bacillus subtilis. After incubation at 37°C for 1824 hours the patches which showed no zone of inhibition on the B. subtilis plate were transferred from the master plate to medium 1 slants and incubated until full growth was evident. Vegetative growth from these slants was transferred to medium 2 and incubated at 37°C on a rotary shaker for 3 days after which portions were streaked as bands about 1-cm wide on the surface of medium 3 plates and incubated at 37°C until growth was evident (3-4 days). Filter paper discs were then saturated with a solution of deoxystreptamine (500 ug/ml) and placed on top of the culture streak. After in- Isolates showing zones of inhibition surrounding the disc were designated as deoxystreptamine idiotrophs. One such mutant which had lost its capacity to produce antibiotic without an exogenous source of deoxystreptamine was designated VIb. This procedure is amenable to screening "non-producing" mutants against a large number of aminocyclitol derivatives.
Strain Improvement Procedures
Micromonspora purpurea mutant VIb was cultivated in medium 2 at 37°C for 3 days and the resultant cells were harvested by centrifugation, washed and resuspended in buffered saline. This suspension was treated with MNNG as above. Samples of the mutagenized culture were plated in medium 3 at 37°C until colonies were evident (7 days). Colonies were picked to duplicate plates containing medium 4.
One set served as a master plate for later recovery whereas the second set contained 25 ug/ml of streptamine sulfate and an overlay spore suspension of B. subtilis as a challenge test organism. These plates were incubated at 37°C for 24 hours and examined for zones of inhibition. Those mutants showing the largest zones were transferred from the master plate onto slants of medium 1 and incubated for one week at 37°C. These mutants were compared with M. purpurea mutant VIb.
First stage seeds of Al. purpurea VIb and the new isolates were prepared by transferring a loopful of vegetative growth from slants into flasks containing medium 2. These were incubated for 4 days at 28°C on a rotary shaker. A 5 % inoculum was then transferred to sets of medium 2 with and without deoxystreptamine (200 ug/ml). These flasks were incubated and assayed daily by the disc diffusion method for antibiotic production. One isolate was selected for comparison with M. purpurea mutant VIb using streptamine. This mutant was designated VIb-3 P.
Screening of Idiotrophs with Potential Precursors
Preliminary detection of antibiotic activity was determined by disc testing of broth which had been supplemented with 500 ug/ml of potential precursor, against B. subtilis. In addition, paper and silica gel chromatography were used. The chromatography systems were (1) Whatman No. 1 paper saturated with 0.95 M sulfate-bisulfate and developed in descending fashion in 90 aqueous ethanol +1.5 % NaCl followed by bioautography using B. subtilis and (2) Silica gel 60 F 254 thin-layer plates (TLC) developed in the lower phase of CHCl,-MeOH-conc. NH3 (28 %)
(1:1:1) followed by bioautography using B. subtilis.
Isolation of New Antibiotics
The antibiotics were obtained from the fermentation broth by adjustment of the pH to 2 with 10 N H2SO4, removal of the cells on filter aid, adjustment of the filtrate to pH 6, followed by ion-exchange chromatography (Bio-Rex 70, Na+ form 2050 mesh). The column was eluted with acid to afford the mixture of antibiotics. The purified antibiotic mixture was then obtained by the isolation procedures described for gentamicin8) The individual components were obtained by preparative thick-layer chromatography (Silica gel PF 254, 1.0 mm x 40 cm x 20 cm plates) using the lower phase of a CHCl3-MeOH-conc. NH3 (28 %) (1:1:1) system. The bands were visualized by spraying the edges and middle of the plate with ninhydrin indicator or by iodine vapor.
Preparation of Aminocyclitols and Characterization of New Antibiotics
All melting points are uncorrected.
The mass spectra reported were measured with a Joelco JMS-I-OCS mass spectrograph.
Infrared spectra were determined on a Model-21 Perkin Elmer infrared spectrophotometer. 1H-NMR spectral measurements were made on a Varian HA-100 spectrophotometer using (Me)4Si as an internal standard. Ultra-violet spectra were recorded on a Cary spectrophotometer Model 15. (11, 12, 13) .15) The mixture of gentamicin C antibiotics produced by supplementation of the growing idiotroph VIb with 2-deoxystreptamine (1) was identical to the gentamicin C mixture produced by the parent strain (M,) when compared by bioautography, (Fig. 3) . The separated components were identical to the three authentic components when compared by mass spectrometry.
Streptamine (2), a close analog of deoxystreptamine (1) successfully afforded new antibiotics when supplemented to growing cultures of deoxystreptamine-requiring mutants of the organisms that produce neomycin,2) paromomycin,2) ribostamycin,3) butirosin,4)and sisomicin.5) A growing culture of M. purpurea VIb when supplemented with streptamine produced a mixture of 2-hydroxygentamicins. The C, component (14) was by far the major component of the mixture with the C. component (15) not visible by bioautography of an isolated crude antibiotic mixture (Fig. 4) . Column chromatography of the crude antibiotic mixture afforded pure 2-hydroxygentamicin C1 (14) . The new antibiotic which was more polar than gentamicin C1 (11) when compared by silica gel thin-layer chromatography was characterized by pmr, ms and analysis of its H2SO4 salt. The mass spectrum showed a molecular ion (493) and major fragments (Fig.  5 ) each 16 mass units (i.e., one oxygen) greater than that obtained from gentamicin C1 (11).16) It was apparent that the biosynthetic pathway to products (C1, C2 and C1a) had been altered when streptamine was supplemented to a culture of mutant VIb and that the shift in ratio of components could be due to the poor antibiotic producing ability of this strain.
By MNNG treatment of mutant VIb and strain selection techniques using streptamine (2) supplementation, another idiotroph of M.
purpurea (VIb-3P) was isolated. This idiotroph afforded the usual mixture of gentamicins (C1, C2 and C1a) when a growing culture was supplemented with 2-deoxystreptamine (1) (Fig. 3) . When streptamine (2) was used a mixture of 2-hydroxygentamicins (C1 and C2; 14 and 15) was obtained. The two components were separated by thick-layer chromatography and characterized by pmr, mass spectrometry and analysis of their H2SO4 salts. The C, (14) component was identical to that obtained from mutant VIb. The mass spectrum of the 2-hydroxygentamicin C2 (15) showed an M+1 peak (480) and major fragments (Fig. 5) , each 16 mass units greater than that obtained from gentamicin C2 (12) .18' Only a trace amount of a more polar antibiotic was isolated from the 2-hydroxygentamicin complex obtained from either mutant to which was assigned the C, a, structure (16) on the basis of a mass spectrum that contained fragments at m/e 129 (purpurosamine) and 160 (garosamine).
The 2-hydroxygentamicin complex (C1, C2, 14, 15) was tested against a series of gramnegative and gram-positive organisms, some of which show gentamicin resistance by the tube dilution technique (Table 1) . The MIC values indicate that 2-hydroxygentamicin has slightly less in vitro activity against gentamicin-sensitive organisms but greater activity against some gentamicin-resistant strains such as E. coli JR 76.2, E. cloacae A20960 and K. pneumoniae A20636 known to contain adenylating R-factor enzymes. 2, 5-Dideoxystreptamine (4), a compound described by SUAMI et al.12)and used by TESTA et al.5) in supplementation studies with an idiotroph of M. inyoensis to yield a 5-deoxy analog of sisomicin, showed antibiotic activity when fed to growing idiotrophs. Such a process using a growing culture of VIb-3P afforded a new complex of antibiotics, 5-deoxygentamicin C1, C2 and C1a (17, 18, 19) . TLC of this C complex indicated that the corresponding analogs to the gentamicin C complex were less polar when developed with the same solvent system. Thicklayer chromatographic separation (silica gel) afforded the C1 (17) and C1a (19) components, which were subjected to mass spectrographic characterization. 5-Deoxygentamicin C1 (17) gave a mass peak at 461, 5-deoxygentamicin Cia (19) gave a mass peak at 433. The C2 component was contaminated with Ci but showed a mass peak at 447. These masses, as well as the major fragments were 16 mass units less than those for the gentamicin C analogs (Fig. 5) . The 5-deoxygentamicin complex (C1, C2, C1a, 17, 18, 19) as well as the individual C, (17) and C1a
(19) components were tested against a series of gram-negative and gram-positive organisms some of which show gentamicin resistance ( Table 2) .
The MIC values of the 5-deoxygentamicin complex were similar to the gentamicin complex against most of the organisms screened. The new antibiotic complex was more active against the gentamicin-resistant E. coli JR-89, which contains the 3-amino (of deoxystreptamine), acetylating enzyme, and P. aeruginosa A20897. It is interesting to note here that the C, component is quite active against P. aeruginosa A20897, an organism that contains the 6'Nacetylating enzyme.
The acute (i.v.) toxicity (LDso) of the 2-hydroxygentamicin C complex was compared to the 5-deoxygentamicin C complex and to gentamicin C complex ( Table 3 ). The relative toxicity of the 2-hydroxygentamicin C complex was about half that of the gentamicin C complex whereas the 5-deoxygentamicin C complex was about 2.5 times as toxic as the gentamicin C complex.
4, 6-Hydrazino-1, 3-cyclohexandiol (5), the synthetic precursor12) of 2, 5-dideoxystreptamine (4), as well as 1, 3-di-N-benzylidine-2, 5-dideoxystreptamine (10) afforded the same 5-deoxygentamicin complex (17, 18, 19) when supplemented to growing cultures of VIb or VIb-3P as shown by silica-gel bioautography. 2-Epistreptamine (3),11) a compound that was successfully bioconverted by the mutant of Streptomyces fradiae1) to hybrimycins B, and B2, also stimulated antibiotic biosynthesis when added to M. purpurea VIb or VIb-3P. The activity observed on a test plate (B. subtilis overlay) was much less than that observed when an equal amount of streptamine was supplemented. This result is not unexpected in light of the activity difference observed by SHIER et al. between hybrimycins A (streptamine analog) and B (epistreptamine analog).'."' Compounds 6, 7, 8, and 9 did not yield antibiotic when fed to growing cultures of these idiotrophs, as was expected.
Deoxystreptamine (1) or 2, 5-dideoxystreptamine (4) are incorporated by the M. purpurea mutant VIb-3P to give the same ratio of C1, C2 and Cia antibiotics as the parent (M,) strain of M. purpurea. Incorporation of streptamine, however, is such that the major components of the C complex of antibiotics produced are almost totally Ci and C,. If one considers the branched pathway suggested by TESTA and TILLY1e' for the production of gentamicins C1, C2
and C" antibiotics from a common precursor antibiotic, then it would appear that streptamine incorporation interferes almost completely with the branch of the biosynthetic pathway leading to C1a.
